AURA · Aura Biosciences, Inc.
$6.98
-0.05 (-0.71%)
At close · Jul 29
Going-concern doubt
— cleared May 11, 2026
The latest filing states the doubt was alleviated.
“As disclosed in the Company's audited consolidated financial statements as of and for the year ended December 31, 2025, events and conditions existed which raised substantial doubt about the Company's ability to continue as a going concern, primarily due to recurring operating losses, negative cash flows from operations and liquidity constraints. Subsequent to year end, the Company completed the 2026 Follow-On Offering, raising approximately $241.8 million in net proceeds after completion of the Matrix Repurchase. Based on the successful execution of this financing, management has concluded that the events and conditions that previously raised substantial doubt have been alleviated.”View the 10-Q filed May 11, 2026
Market Cap
$717.50M
Shares
103.39M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$106.19M
-22.2%
FY2025
Diluted EPS
-$1.76
-0.6%
FY2025
Operating Cash Flow
-$84.74M
-6.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $94.92M | $90.3M | $73.3M | $65.23M | $42.24M | $25.16M | $18.04M | |
| $23.71M | $22.49M | $22.81M | $19.76M | $18.06M | $10.09M | $4.16M | |
| -$118.62M | -$112.79M | -$96.12M | -$84.99M | -$60.3M | -$35.25M | -$22.21M | |
| $6.33M | $6.71M | $9.31M | $8.72M | $1.53M | -$1000 | — | |
| — | — | — | — | -$9000 | — | — | |
| -$112.29M | -$106.08M | -$86.81M | -$76.27M | -$58.76M | — | — | |
| $101K | $108K | $112K | $137K | $0 | $0 | $0 | |
| -$112.39M | -$106.19M | -$86.92M | -$76.41M | -$58.76M | -$35.25M | -$22.21M | |
| -$112.71M | -$106.56M | -$87.2M | -$75.8M | -$58.84M | -$35.25M | — | |
| USD/shares | — | -$1.76 | -$1.75 | -$1.93 | -$1.96 | -$8.95 | — |
| USD/shares | — | -$1.76 | -$1.75 | -$1.93 | -$1.96 | -$8.95 | — |
| shares | — | 60.34M | 49.65M | 39.62M | 29.94M | 5.16M | 367.2K |
| shares | — | 60.34M | 49.65M | 39.62M | 29.94M | 5.16M | 367.2K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.45×
EV/EBIT
—
Peer median 24.64×
P/E (TTM)
—
Peer median 10.79×
Peer medians compare against the 301 similar-size Biotechnology companies (of 522 listed).
Key facts
CIK
1501796
CUSIP
05153U107
13F (30d)
18 filings
18 filers
Visit website
Investor relations